Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 26, Issue 2, 2011, Pages 646-652

  Cianciolo, Giuseppe ^a   La Manna, Gaetano ^a   Donati, Gabriele ^a   Dormi, Ada ^b   Cappuccilli, Maria L ^a   Cuna, Vania ^a   Legnani, Cristina ^a   Palareti, Gualtiero ^a   Col, Luigi ^a   Stefoni, Sergio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

end stage renal disease; haemodialysis; low molecular weight heparin; osteoprotegerin; unfractioned heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW MOLECULAR WEIGHT HEPARIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

ADULT; AGED; ANTICOAGULANTS; CROSS-OVER STUDIES; CYTOKINES; FACTOR XA; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RANK LIGAND; RENAL DIALYSIS;

EID: 79551503140     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq421     Document Type: Article

References (35)

1. Schulman S, Hellgren-Wångdahl M. Pregnancy, heparin and osteoporosis. Thromb Haemost 2002; 87: 180-181
2. Folwarczna J, Sliwinski L, Janiec Wet al. Effects of standard heparin and low molecular weight heparins on the formation of murine osteoclasts in vivo. Pharmacol Rep 2005; 57: 635-645
3. Muir JM, Hirsh J, Weitz JI. A histomorphometric comparison of the effects of low molecular weight heparin on cancellous bone in rats. Blood 1997; 89: 3236-3242
4. Petilla V, Leinonen P, Markkola A. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractioned heparin or LMW heparin. Thromb Haemost 2002; 87: 182-186
5. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95: 1046-1057
6. Vega D, Maalouf NM, Sakhaee K et al. The role of receptor activator of nuclear factor-KB (RANK)/RANK ligand/osteoprotegerin: clinical implication. J Clin Endocrinol Metab 2007; 92: 4514-4521
7. Matsubara K, Stenvinkel P, Qureshi AR et al. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol 2009; 22: 774-782
8. Valentin S, Larnkjer A, Ostergaard Pet al. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994; 75: 173-183
9. McGonigle JS, Giacchelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009; 12: 35-46
10. VikA, Brodin E, Sveinbjornsson B et al. Heparin induces mobilization of osteoprotegerin in to the circulation. Thromb Haemost 2007; 98: 148-154
11. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 2004; 15: 3192-3206
12. Stefoni S, Cianciolo G, Donati G et al. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis. Nephron 2002; 92: 589-600
13. Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-362
14. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism. Mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
15. van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009; 204: 321-329
16. Nybo M, Rasmussen LM. Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells. Atherosclerosis 2008; 201: 33-35
17. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319
18. Morena M, Terrier N, Jaussent I. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006; 17: 262-270
19. Nitta K, Akiba T, Uchida K. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1886-1889
20. Barreto DV, Barreto FC, Carvalho AB et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremiarelated risk factors. Kidney Int 2005; 67: 1576-1582
21. Zimmermann J, Herrlinger S, Pruy A. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658
22. Kim SM, Lee J, Ryu OH et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol 2005; 63: 594-598
23. Pecoits-Filho R, Lindolm B, Stenvinkel P. The malnutrition, inflammation and atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol Dial Transplant 2002; 17: 28-31
24. Saxena U, Klein MG, Goldberg IJ. Transport of lipoprotein lipase across endothelial cells. Proc Natl Acad Sci USA 1991; 188: 2254-2258
25. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813
26. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22: 549-553
27. Kiechl S, Schett G, Wenning G et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180
28. Malyankar UM, Scatena M, Suchland KL et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cell. J Biol Chem 2000; 275: 20959-20962
29. Sattler AM, Schoppet M, Schaefer JR et al. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004; 74: 103-106
30. Bennett BJ, Scatena M, Kirk EA et al. Osteoprotegerin activation accelerates advanced atherosclerotics lesion progression and calcification in older ApoE?/? mice. Atheroscler Thromb Vasc Biol 2006; 26: 2117-2124
31. Morony S, Tintut Y, Zang Z et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr (?/?) mice. Circulation 2008; 117: 411-420
32. Kiechl S, Werner P, Knoflach M et al. The osteoprotegerin/RANK/ RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006; 4: 801-811
33. Crisafulli A, Micari A, Altavilla D et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci 2005; 109: 389-395
34. Abedin M, Omland T, Ueland T et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (form the Dallas Heart Study). Am J Cardiol 2007; 99: 513-518
35. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fracture and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-637